HHS Overrules FDA On Plan B OTC, Sends Teva Back To Drawing Board
This article was originally published in The Pink Sheet Daily
Executive Summary
HHS Secretary Sebelius’ override appears to set a precedent of HHS intervention in an FDA product review.